Summit Therapeutics Inc. (SMMT) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2024-12-31..
Operating margin
Overview →Financial period ending 2024-12-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2024-12-31. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -226.00M USD | Operating Income (Loss) |
| Revenue | 0.00 USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | (m) | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2024-12-31 | $-226.00M | $0.00 | (m) | (m) | (m) | (m) |
| 2024-09-30 | $-196.59M | $0.00 | (m) | (m) | (m) | (m) |
| 2024-06-30 | $-158.71M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $-114.89M | (m) | (m) | $80.46M | (m) | (m) |
| 2023-12-31 | $-609.65M | $0.00 | (m) | $59.47M | (m) | (m) |
| 2023-09-30 | $-593.74M | $0.00 | (m) | $40.04M | (m) | (m) |
| 2023-06-30 | $-590.19M | $220.00K | (m) | $41.77M | (m) | -268266.82% |
| 2023-03-31 | $-587.09M | $455.00K | (m) | $41.33M | (m) | -129029.67% |
| 2022-12-31 | $-72.09M | $705.00K | (m) | $52.00M | (m) | -10225.39% |
| 2022-09-30 | $-77.84M | $956.00K | (m) | $69.72M | (m) | -8141.95% |
| 2022-06-30 | $-80.38M | $2.04M | (m) | $72.61M | (m) | -3930.71% |
| 2022-03-31 | $-91.42M | $1.87M | (m) | $87.53M | (m) | -4896.68% |
| 2021-12-31 | $-86.19M | $1.81M | (m) | $85.35M | (m) | -4764.29% |
| 2021-09-30 | $-71.69M | $1.74M | (m) | $75.31M | (m) | -4113.31% |
| 2021-06-30 | $-69.15M | $615.00K | (m) | $69.09M | (m) | -11243.90% |
| 2021-03-31 | $-60.78M | $728.00K | (m) | $58.74M | (m) | -8348.35% |
| 2020-12-31 | $-53.19M | $860.00K | (m) | $53.27M | (m) | -6185.23% |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-01-31 | $6.00M | $57.09M | (m) | $52.00M | (m) | 10.52% |
| 2018-01-31 | $-28.37M | $16.10M | (m) | $37.72M | (m) | -176.15% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |